Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

CTSO has been the subject of a number of other research reports. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a strong-buy rating in a research report on Monday, July 29th. HC Wainwright reissued a neutral rating and set a $1.00 target price on shares of Cytosorbents in a research report on Wednesday, August 14th.

Cytosorbents Price Performance

Shares of CTSO opened at $1.08 on Friday. The company has a 50 day moving average price of $1.05 and a 200-day moving average price of $0.94. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $2.15. The stock has a market capitalization of $58.78 million, a PE ratio of -1.83 and a beta of 0.50. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.71 and a current ratio of 2.12.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. The company had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $9.73 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. Equities analysts predict that Cytosorbents will post -0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CTSO. Key Client Fiduciary Advisors LLC raised its holdings in shares of Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares during the last quarter. CM Management LLC increased its stake in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares during the period. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares during the period. Neuberger Berman Group LLC increased its stake in shares of Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the period. Finally, Avenir Corp increased its stake in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.